Cargando…
Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a...
Autores principales: | Ulm, Michael, Ramesh, Arvind V, McNamara, Keely M, Ponnusamy, Suriyan, Sasano, Hironobu, Narayanan, Ramesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365668/ https://www.ncbi.nlm.nih.gov/pubmed/30640710 http://dx.doi.org/10.1530/EC-18-0425 |
Ejemplares similares
-
Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer
por: Narayanan, Ramesh, et al.
Publicado: (2017) -
Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer
por: Ulm, Michael A., et al.
Publicado: (2020) -
Phase Two Steroid Metabolism and Its Roles in Breast and Prostate Cancer Patients
por: McNamara, Keely M., et al.
Publicado: (2013) -
An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
por: Mohler, Michael L., et al.
Publicado: (2021) -
Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers
por: Ponnusamy, Suriyan, et al.
Publicado: (2019)